Author:
Hua Qingchu,Wang Wei,Qu Gengcuo,Pei Wenjie,Chen Yue
Abstract
Abstract
The flare phenomenon is a transient increase in the number or intensity of lesions on bone scans after treatment, signifying curative effect. DOTA-ibandronic acid (DOTA-IBA) is a new prodrug that targets bone metastases and can be labeled with 177Lu. Here, we report the case of a 58-year-old woman with bone metastasis, in whom the flare phenomenon was observed after 4 cycles of 177Lu-DOTA-IBA treatment. No adverse effects were observed during the treatment and follow-up periods.
Publisher
Ovid Technologies (Wolters Kluwer Health)